$MBRXSep 23, 2026, 8:25 AM ETAI processed
Moleculin (MBRX) wins Mexican patent for lung-targeted liposomal Annamycin through 2040
AI Summary
Moleculin (MBRX) said the Mexican Patent Office granted Patent No. 436849, protecting its lung-targeted liposomal formulation of Annamycin until Nov. 23, 2040. The company says the patent strengthens Annamycin's global IP estate and supports potential development into pulmonary tumors and lung metastases while the drug advances in the pivotal MIRACLE Phase 2/3 trial for relapsed/refractory AML (Annamycin + cytarabine).
Positives
- Mexican Patent No. 436849 issued, providing exclusivity for lung-targeted liposomal Annamycin until Nov 23, 2040
- Patent specifically covers a formulation designed to enhance delivery to pulmonary tumors and lung metastases, expanding potential indications beyond AML
- Annamycin is currently in a pivotal MIRACLE Phase 2/3 trial (combination with cytarabine) after prior Phase 1B/2 work with FDA input
Negatives
- Patent grant does not guarantee regulatory approval, safety, or commercial success
- Pivotal MIRACLE trial is ongoing and efficacy/safety outcomes remain unproven
- Company states it will require significant additional financing to conduct clinical trials and has no financing commitments